Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bravecto Quantum (fluralaner for extended-release injectable suspension)** is a long-acting parasiticide for dogs indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations, specifically Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Rhipicephalus sanguineus (brown dog tick) for 12 months, and Amblyomma americanum (lone star tick) for 8 months in dogs and puppies 6 months of age and older[1][3][13]. The active ingredient, fluralaner, is an isoxazoline-class agent that inhibits arthropod nervous system function by targeting gamma-aminobutyric acid (GABA)- and glutamate-gated chloride channels, leading to paralysis and death of fleas and ticks[2]. It is administered as a single subcutaneous injection. The unique extended-release formulation provides continuous efficacy for up to a year, reducing the need for monthly or spot-on treatments[3][6]. Side effects are uncommon but may include mild, temporary injection site reactions, and very rarely neurologic adverse events such as seizures[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bravecto quantum.